FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3158782175> ?p ?o ?g. }

• W3158782175 endingPage "5" @default.
• W3158782175 startingPage "1" @default.
• W3158782175 abstract "Background: The use of substandard and falsified (SF) anti-tuberculosis (ant-TB) medicines may lead to treatment failure and development of drug resistance. SF medicinal products are claimed to be more prevalent in developing countries with high burden of tuberculosis disease. National Regulatory Authorities therefore, should ensure that the quality of these life-saving medicines is systematically monitored. We conducted a post marketing surveillance study to determine the quality of anti-tuberculosis medicines circulating on the market in Tanzania Mainland. Methods: This was a prospective cross sectional study conducted between 2012 and 2018. Purposive sampling technique was used in collecting a total of 777 samples of anti-tuberculosis medicines. Samples were collected from ports of entry, Medical Stores Department (MSD) and healthcare facilities in 16 regions of Tanzania Mainland. All collected samples were subjected quality screening using Global Pharma Health Fund® (GPHF) Mini-Lab kits. Only samples collected from MSD and healthcare facilities were subjected to product information review. Samples collected from MSD and healthcare facilities that did not comply with GPHF protocol requirements or yielded doubtful results and ten percent (10%) of all those that complied were subjected to tier II confirmatory testing using full pharmacopoeia monographs at the Tanzania Medicines and Medical Device (TMDA) Quality Control Laboratory which is prequalified by the World Health Organization. Results: All 777 collected samples complied with the requirements of both GPHF minilab protocol and respective compendial monographs when subjected to screening and confirmatory testing, respectively. Of the samples collected from medicine distribution outlets 71.3% (176/247) samples did not comply with product information requirements as per TMDA labelling requirements and approved product information. Conclusion: These Results calls for continuously reinforcing and monitoring of Ant-TB medicines to ensure that only those of good quality and proper information are circulating on the Tanzanian mainland market." @default.
• W3158782175 created "2021-05-10" @default.
• W3158782175 creator A5001533384 @default.
• W3158782175 creator A5019830800 @default.
• W3158782175 creator A5019892848 @default.
• W3158782175 creator A5021860981 @default.
• W3158782175 creator A5025308866 @default.
• W3158782175 creator A5036045705 @default.
• W3158782175 creator A5040514250 @default.
• W3158782175 creator A5051645303 @default.
• W3158782175 creator A5054454125 @default.
• W3158782175 creator A5058630110 @default.
• W3158782175 creator A5060288820 @default.
• W3158782175 creator A5066018113 @default.
• W3158782175 creator A5068221001 @default.
• W3158782175 creator A5075076033 @default.
• W3158782175 creator A5086638069 @default.
• W3158782175 date "2021-01-01" @default.
• W3158782175 modified "2023-09-24" @default.
• W3158782175 title "Quality Surveillance of Anti-Tuberculosis Medicines in Tanzania, 2012-2018" @default.
• W3158782175 doi "https://doi.org/10.35248/2329-9088.21.9.232" @default.
• W3158782175 hasPublicationYear "2021" @default.
• W3158782175 type Work @default.
• W3158782175 sameAs 3158782175 @default.
• W3158782175 citedByCount "0" @default.
• W3158782175 crossrefType "journal-article" @default.
• W3158782175 hasAuthorship W3158782175A5001533384 @default.
• W3158782175 hasAuthorship W3158782175A5019830800 @default.
• W3158782175 hasAuthorship W3158782175A5019892848 @default.
• W3158782175 hasAuthorship W3158782175A5021860981 @default.
• W3158782175 hasAuthorship W3158782175A5025308866 @default.
• W3158782175 hasAuthorship W3158782175A5036045705 @default.
• W3158782175 hasAuthorship W3158782175A5040514250 @default.
• W3158782175 hasAuthorship W3158782175A5051645303 @default.
• W3158782175 hasAuthorship W3158782175A5054454125 @default.
• W3158782175 hasAuthorship W3158782175A5058630110 @default.
• W3158782175 hasAuthorship W3158782175A5060288820 @default.
• W3158782175 hasAuthorship W3158782175A5066018113 @default.
• W3158782175 hasAuthorship W3158782175A5068221001 @default.
• W3158782175 hasAuthorship W3158782175A5075076033 @default.
• W3158782175 hasAuthorship W3158782175A5086638069 @default.
• W3158782175 hasConcept C142724271 @default.
• W3158782175 hasConcept C144024400 @default.
• W3158782175 hasConcept C15744967 @default.
• W3158782175 hasConcept C160735492 @default.
• W3158782175 hasConcept C162324750 @default.
• W3158782175 hasConcept C180747234 @default.
• W3158782175 hasConcept C204787440 @default.
• W3158782175 hasConcept C2779356329 @default.
• W3158782175 hasConcept C2779357621 @default.
• W3158782175 hasConcept C2780385302 @default.
• W3158782175 hasConcept C2781069245 @default.
• W3158782175 hasConcept C45355965 @default.
• W3158782175 hasConcept C50522688 @default.
• W3158782175 hasConcept C512399662 @default.
• W3158782175 hasConcept C556039675 @default.
• W3158782175 hasConcept C71924100 @default.
• W3158782175 hasConcept C99454951 @default.
• W3158782175 hasConceptScore W3158782175C142724271 @default.
• W3158782175 hasConceptScore W3158782175C144024400 @default.
• W3158782175 hasConceptScore W3158782175C15744967 @default.
• W3158782175 hasConceptScore W3158782175C160735492 @default.
• W3158782175 hasConceptScore W3158782175C162324750 @default.
• W3158782175 hasConceptScore W3158782175C180747234 @default.
• W3158782175 hasConceptScore W3158782175C204787440 @default.
• W3158782175 hasConceptScore W3158782175C2779356329 @default.
• W3158782175 hasConceptScore W3158782175C2779357621 @default.
• W3158782175 hasConceptScore W3158782175C2780385302 @default.
• W3158782175 hasConceptScore W3158782175C2781069245 @default.
• W3158782175 hasConceptScore W3158782175C45355965 @default.
• W3158782175 hasConceptScore W3158782175C50522688 @default.
• W3158782175 hasConceptScore W3158782175C512399662 @default.
• W3158782175 hasConceptScore W3158782175C556039675 @default.
• W3158782175 hasConceptScore W3158782175C71924100 @default.
• W3158782175 hasConceptScore W3158782175C99454951 @default.
• W3158782175 hasIssue "2" @default.
• W3158782175 hasLocation W31587821751 @default.
• W3158782175 hasOpenAccess W3158782175 @default.
• W3158782175 hasPrimaryLocation W31587821751 @default.
• W3158782175 hasRelatedWork W1569659466 @default.
• W3158782175 hasRelatedWork W1969424827 @default.
• W3158782175 hasRelatedWork W2017612807 @default.
• W3158782175 hasRelatedWork W2048723245 @default.
• W3158782175 hasRelatedWork W2075998755 @default.
• W3158782175 hasRelatedWork W2079199032 @default.
• W3158782175 hasRelatedWork W2090772679 @default.
• W3158782175 hasRelatedWork W2098306290 @default.
• W3158782175 hasRelatedWork W2192327024 @default.
• W3158782175 hasRelatedWork W2354588221 @default.
• W3158782175 hasRelatedWork W2531136632 @default.
• W3158782175 hasRelatedWork W2590690511 @default.
• W3158782175 hasRelatedWork W2592891629 @default.
• W3158782175 hasRelatedWork W2803662246 @default.
• W3158782175 hasRelatedWork W2910585155 @default.
• W3158782175 hasRelatedWork W3029706120 @default.
• W3158782175 hasRelatedWork W3082326709 @default.
• W3158782175 hasRelatedWork W3125942986 @default.
• W3158782175 hasRelatedWork W3133714353 @default.

• next